Endocrinology, Diabetes & Metabolism (Apr 2021)

RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes

  • Rachel Adams,
  • Nicole Daly,
  • Elizabeth Robertson,
  • Giuseppe N. Giordano

DOI
https://doi.org/10.1002/edm2.207
Journal volume & issue
Vol. 4, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource‐intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at‐risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.

Keywords